The effect of elranatamab against multiple myeloma cells is mediated by CD8+ cellsTakaaki Takeda, Hideaki Nakajima, Yuki Nakajima et al.|SSRN Electronic Journal|2026Cited by 1
Efficacy and Safety of Ponatinib as a Second‑Line Treatment for Chronic‑Phase Chronic Myeloid Leukemia: Retrospective Study at Two Japanese CentersYoshimi Ishii, Hideaki Nakajima, Kota Kawabata et al.|Indian Journal of Hematology and Blood Transfusion|2026Cited by 0
[Delayed response with peripheral blood CD8<sup>+</sup> T cell expansion during elranatamab therapy in relapsed/refractory multiple myeloma].Ayako Bouno, Hideaki Nakajima, Yuki Nakajima et al.|PubMed|2026Cited by 0
Systemic CD5-Positive Diffuse Large B-cell Lymphoma Preceded by Intravascular Large B-cell Lymphoma-like Features in the Prostate: A Case ReportYuki Nakajima, Hideaki Nakajima, Takaaki Takeda et al.|Internal Medicine|2026Cited by 0